May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Systemic Betablocker Treatment With Nebivolol Enhances Ocular Hemodynamics in Glaucoma Patients With Arterial Hypertension
Author Affiliations & Notes
  • P.C. Galambos
    Klinik und Poliklinik fuer Augenheilkunde, Universitaetsklinikum Hamburg–Eppendorf, Germany
  • N. Matthiesen
    Klinik und Poliklinik fuer Augenheilkunde, Universitaetsklinikum Hamburg–Eppendorf, Germany
  • L. Wagenfeld
    Klinik und Poliklinik fuer Augenheilkunde, Universitaetsklinikum Hamburg–Eppendorf, Germany
  • A. Wiermann
    Klinik und Poliklinik fuer Augenheilkunde, Universitaetsklinikum Hamburg–Eppendorf, Germany
  • R. Praga
    Klinik und Poliklinik fuer Augenheilkunde, Universitaetsklinikum Hamburg–Eppendorf, Germany
  • E.T. Matthiessen
    Klinik und Poliklinik fuer Augenheilkunde, Universitaetsklinikum Hamburg–Eppendorf, Germany
  • G. Richard
    Klinik und Poliklinik fuer Augenheilkunde, Universitaetsklinikum Hamburg–Eppendorf, Germany
  • M. Klemm
    Klinik und Poliklinik fuer Augenheilkunde, Universitaetsklinikum Hamburg–Eppendorf, Germany
  • O. Zeitz
    Klinik und Poliklinik fuer Augenheilkunde, Universitaetsklinikum Hamburg–Eppendorf, Germany
  • Footnotes
    Commercial Relationships  P.C. Galambos, Berlin–Chemie, F; N. Matthiesen, Berlin–Chemie, F; L. Wagenfeld, None; A. Wiermann, None; R. Praga, None; E.T. Matthiessen, None; G. Richard, None; M. Klemm, None; O. Zeitz, Berlin–Chemie, F.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 485. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P.C. Galambos, N. Matthiesen, L. Wagenfeld, A. Wiermann, R. Praga, E.T. Matthiessen, G. Richard, M. Klemm, O. Zeitz; Systemic Betablocker Treatment With Nebivolol Enhances Ocular Hemodynamics in Glaucoma Patients With Arterial Hypertension . Invest. Ophthalmol. Vis. Sci. 2006;47(13):485.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Treatment of arterial hypertension potentially leads to a reduction of ocular blood flow by lowering perfusion pressure. Aim of the present study was to investigate the effect of nebivolol, a systemic beta–blocker with NO–releasing and vasodilatory qualities, on the blood flow velocities in the retrobulbar vasculature.

Methods: : Peak systolic velocity (PSV) and end–diastolic velocity (EDV) in the short and long posterior ciliary artery (SPCA, LPCA), central retinal artery (CRA) and ophthalmic artery (OA) were recorded by color Doppler imaging (CDI) in 13 glaucoma patients with arterial hypertension before and 4 weeks after a switch of systemic antihypertensive betablocker medication to nebivolol.

Results: : Four weeks after a switch to nebivolol therapy CDI measurements revealed a significant acceleration of the PSV (8.9±0.7cms–1 vs 11.5±0.9cms–1; P=0.023) and EDV (1.9±0.1cms–1 vs 2.4±0.2cms–1; P=0.048) in the SPCA and PSV (13.2±1.3cms–1 vs 16.1±1.1cms–1; P=0.027) of the LPCA. EDV of LPCA (2.5±0.3cms–1 vs 3.2±0.4cms–1; P=0.072) was noticeably but statistically non–significantly increased. No significant differences in flow velocities were found for the CRA and OA. IOP and systemic blood pressure remained unchanged.

Conclusions: : Blood pressure treatment with nebivolol leads to an acceleration of perfusion in the vessels crucial for the blood supply to the optic nerve head. The present data are the basis for a double–blinded and randomized trial conducted at our eye clinic in order to investigate beneficial effects of nebivolol in glaucoma patients and evaluate whether nebivolol should be a preferred systemic antihypertensive beta–blocker treatment in glaucoma patients suffering from arterial hypertension.

Keywords: blood supply • optic disc • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×